Phase II study of Gleevec ® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

Journal of Neuro-Oncology

Volumn 106, Issue 2, 2012, Pages 409-415

  Reardon, David A ^a   Norden, Andrew D ^b   Desjardins, Annick ^a   Vredenburgh, James J ^a   Herndon II, James E ^a   Coan, April ^a   Sampson, John H ^a   Gururangan, Sridharan ^a   Peters, Katherine B ^a   McLendon, Roger E ^a   Norfleet, Julie A ^a   Lipp, Eric S ^a   Drappatz, Jan ^b   Wen, Patrick Y ^b   Friedman, Henry S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Hydroxyurea; Imatinib mesylate; Meningioma; Platelet derived growth factor receptor

Indexed keywords

BCR ABL PROTEIN; CYTOCHROME P450 3A; HYDROXYUREA; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; STEM CELL FACTOR;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; HUMAN; HYPOALBUMINEMIA; HYPOPHOSPHATEMIA; INFECTION; MALE; MENINGIOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ONCOGENE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; RECURRENT CANCER; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYDROXYUREA; KAPLAN-MEIER ESTIMATE; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PYRIMIDINES;

EID: 82955235715     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0687-1     Document Type: Article

References (41)

1. CBTRUS (2004-2006) 2010 Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2006. Central Brain Tumor Registry of the United States
2. C Mawrin A Perry 2010 Pathological classification and molecular genetics of meningiomas J Neurooncol 99 379 391 10.1007/s11060-010-0342-2 20809251 10.1007/s11060-010-0342-2 1:CAS:528:DC%2BC3cXht1Sru77L
3. O Al-Mefty PA Kadri S Pravdenkova JR Sawyer C Stangeby M Husain 2004 Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings J Neurosurg 101 210 218 10.3171/jns.2004.101.2.0210 15309910 10.3171/jns.2004.101.2.0210 (Pubitemid 38970995)
4. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer (IARC), Lyon
5. U.S. Department of Health and Human Services CfDE, and Research FaDa (2006) FDA project on cancer drug approval endpoint
6. L Rogers M Gilbert MA Vogelbaum 2010 Intracranial meningiomas of atypical (WHO grade II) histology J Neurooncol 99 393 405 10.1007/s11060-010-0343-1 20740303 10.1007/s11060-010-0343-1
7. S Hanft P Canoll JN Bruce 2010 A review of malignant meningiomas: diagnosis, characteristics, and treatment J Neurooncol 99 433 443 10.1007/s11060-010-0348-9 20730473 10.1007/s11060-010-0348-9 1:CAS:528:DC%2BC3cXht1Sru7%2FM
8. MK Aghi BS Carter GR Cosgrove RG Ojemann S Amin-Hanjani RL Martuza WT Curry Jr FG Barker 2nd 2009 Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation Neurosurgery 64 56 60 10.1227/01.NEU.0000330399.55586.63 19145156 10.1227/01.NEU.0000330399.55586.63 discussion 60
9. MC Chamberlain DD Tsao-Wei S Groshen 2004 Temozolomide for treatment-resistant recurrent meningioma Neurology 62 1210 1212 15079029 1:CAS:528:DC%2BD2cXktFGjtLo%3D (Pubitemid 38456523)
10. MC Chamberlain DD Tsao-Wei S Groshen 2006 Salvage chemotherapy with CPT-11 for recurrent meningioma J Neurooncol 78 271 276 16628476 10.1007/s11060-005-9093-x 1:CAS:528:DC%2BD28Xpt1ylt7g%3D
11. DR Johnson DW Kimmel PA Burch TL Cascino C Giannini W Wu JC Buckner 2011 Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma Neuro Oncol 13 530 535 10.1093/neuonc/nor044 21558077 10.1093/neuonc/nor044 1:CAS:528: DC%2BC3MXovFWqtLo%3D
12. MC Chamberlain MJ Glantz L Chalmers A Van Horn AE Sloan 2007 Early necrosis following concurrent temodar and radiotherapy in patients with glioblastoma J Neurooncol 82 81 83 16944309 10.1007/s11060-006-9241-y
13. MC Chamberlain MJ Glantz 2008 Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas Cancer 113 2146 2151 18756531 10.1002/cncr.23803 1:CAS:528:DC%2BD1cXht12lu77I
14. SM Grunberg MH Weiss CA Russell IM Spitz J Ahmadi A Sadun R Sitruk-Ware 2006 Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma Cancer Invest 24 727 733 10.1080/ 07357900601062339 17162554 10.1080/07357900601062339 1:CAS:528: DC%2BD2sXhs1WntLc%3D (Pubitemid 44949876)
15. SW Lamberts HL Tanghe CJ Avezaat R Braakman R Wijngaarde JW Koper H De Jong 1992 Mifepristone (RU 486) treatment of meningiomas J Neurol Neurosurg Psychiatry 55 486 490 1619417 10.1136/jnnp.55.6.486 1:STN:280: DyaK38zhsl2gtA%3D%3D
16. AD Norden J Raizer L Abrey K Lamborn A Lassman SM Chang WKA Yung M Gilbert HA Fine M Mehta L De Angelis T Cloughesy HI Robins K Aldape J Dancey M Prodos F Lieberman PY Wen 2009 Phase II Trials of erlotinb or gefitinib in patients with recurrent meningioma J Neurooncol 96 2 211 217 19562255 10.1007/s11060-009-9948-7
17. HB Newton 2007 Hydroxyurea chemotherapy in the treatment of meningiomas Neurosurg Focus 23 E11 17961035 10.3171/FOC-07/10/E11
18. HB Newton SR Scott C Volpi 2004 Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up Br J Neurosurg 18 495 499 15799152 10.1080/02688690400012392 1:STN:280:DC%2BD2M7mslahsQ%3D%3D (Pubitemid 40076195)
19. HB Newton MA Slivka C Stevens 2000 Hydroxyurea chemotherapy for unresectable or residual meningioma J Neurooncol 49 165 170 11206012 10.1023/A:1026770624783 1:STN:280:DC%2BD3M7nvV2jtg%3D%3D (Pubitemid 32058523)
20. D Loven R Hardoff ZB Sever AP Steinmetz M Gornish ZH Rappaport E Fenig Z Ram A Sulkes 2004 Non-resectable slow-growing meningiomas treated by hydroxyurea J Neurooncol 67 221 226 15072471 10.1023/B:NEON.0000021827.85754.8e (Pubitemid 38418272)
21. WP Mason F Gentili DR Macdonald S Hariharan CR Cruz LE Abrey 2002 Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma J Neurosurg 97 341 346 10.3171/jns.2002.97.2.0341 12186462 10.3171/jns.2002.97.2.0341 1:CAS:528:DC%2BD38XmsF2rtLs%3D (Pubitemid 34827334)
22. MA Rosenthal DL Ashley L Cher 2002 Treatment of high risk or recurrent meningiomas with hydroxyurea J Clin Neurosci 9 156 158 10.1054/jocn.2001.1019 11922703 10.1054/jocn.2001.1019 (Pubitemid 34464585)
23. UM Schrell MG Rittig M Anders UH Koch R Marschalek F Kiesewetter R Fahlbusch 1997 Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. decrease in the size of meningiomas in patients treated with hydroxyurea J Neurosurg 86 840 844 9126900 10.3171/jns.1997.86.5.0840 1:CAS:528:DyaK2sXms12ht70%3D (Pubitemid 27187687)
24. BM Hahn UM Schrell R Sauer R Fahlbusch O Ganslandt GG Grabenbauer 2005 Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study J Neurooncol 74 157 165 10.1007/s11060-004-2337-3 16193387 10.1007/s11060-004-2337-3 1:CAS:528:DC%2BD2MXht12hurjI (Pubitemid 41478912)
25. BT Ragel RL Jensen 2010 Aberrant signaling pathways in meningiomas J Neurooncol 99 315 324 10.1007/s11060-010-0381-8 20838852 10.1007/s11060-010- 0381-8 1:CAS:528:DC%2BC3cXht1Sru77F
26. Yang SY, Xu GM (2001) Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas. J Clin Neurosci 8 Supplement 1:49-53. doi: 10.1054/jocn.2001.0877 (Pubitemid 32666672)
27. G Nagashima J Asai R Suzuki T Fujimoto 2001 Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression Brain Tumor Pathol 18 1 5 11517968 10.1007/BF02478918 1:STN:280:DC%2BD3MvnsVGgug%3D%3D
28. T Todo EF Adams R Fahlbusch T Dingermann H Werner 1996 Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor J Neurosurg 84 852 858 8622161 10.3171/jns.1996.84.5.0852 1:CAS:528: DyaK28XjtFKmu74%3D discussion 858-859
29. A Mauro A Di Sapio C Mocellini D Schiffer 1995 Control of meningioma cell growth by platelet-derived growth factor (PDGF) J Neurol Sci 131 135 143 7595638 10.1016/0022-510X(95)00106-C 1:CAS:528:DyaK2MXnslSgtrw%3D
30. UM Schrell S Gauer F Kiesewetter A Bickel J Hren EF Adams R Fahlbusch 1995 Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop J Neurosurg 82 600 607 10.3171/jns.1995.82.4.0600 7897522 10.3171/jns.1995.82.4.0600 1:CAS:528:DyaK2MXlt1ehtLw%3D
31. JI Kuratsu H Seto M Kochi Y Ushio 1994 Expression of PDGF, PDGF-receptor, EGF-receptor and sex hormone receptors on meningioma Acta Neurochir (Wien) 131 289 293 10.1007/BF01808629 1:STN:280:DyaK2M3nsVCmtQ%3D%3D
32. D Figarella-Branger AM Vagner-Capodano P Bouillot N Graziani D Gambarelli B Devictor H Zattara-Cannoni N Bianco F Grisoli JF Pellissier 1994 Platelet-derived growth factor (PDGF) and receptor (PDGFR) expression in human meningiomas: correlations with clinicopathological features and cytogenetic analysis Neuropathol Appl Neurobiol 20 439 447 7531297 10.1111/j.1365-2990.1994. tb00994.x 1:STN:280:DyaK2M7kvVSntw%3D%3D (Pubitemid 24326466)
33. PM Black R Carroll D Glowacka K Riley K Dashner 1994 Platelet-derived growth factor expression and stimulation in human meningiomas J Neurosurg 81 388 393 10.3171/jns.1994.81.3.0388 8057146 10.3171/jns.1994.81.3.0388 1:STN:280:DyaK2czjsVOhtw%3D%3D (Pubitemid 24267646)
34. M Maxwell T Galanopoulos ET Hedley-Whyte PM Black HN Antoniades 1990 Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products Int J Cancer 46 16 21 2163990 10.1002/ijc.2910460106 1:STN:280:DyaK3czgsleisQ%3D%3D (Pubitemid 20225781)
35. MD Johnson E Okedli A Woodard SA Toms GS Allen 2002 Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells J Neurosurg 97 668 675 10.3171/jns.2002.97.3.0668 12296652 10.3171/jns.2002.97.3. 0668 1:CAS:528:DC%2BD38XnsFOjtrs%3D (Pubitemid 34994385)
36. MD Johnson A Woodard P Kim M Frexes-Steed 2001 Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells J Neurosurg 94 293 300 10.3171/jns.2001.94.2.0293 11213968 10.3171/jns.2001.94.2.0293 1:CAS:528:DC%2BD3MXhtF2mtrs%3D (Pubitemid 32799692)
37. DA Reardon MJ Egorin JA Quinn JN Rich Sr I Gururangan JJ Vredenburgh A Desjardins S Sathornsumetee JM Provenzale JE Herndon 2nd JM Dowell MA Badruddoja RE McLendon TF Lagattuta KP Kicielinski G Dresemann JH Sampson AH Friedman AJ Salvado HS Friedman 2005 Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme J Clin Oncol 23 9359 9368 16361636 10.1200/JCO.2005.03.2185 1:CAS:528:DC%2BD28Xnt1ymsw%3D%3D
38. PY Wen WK Yung KR Lamborn PL Dahia Y Wang B Peng LE Abrey J Raizer TF Cloughesy K Fink M Gilbert S Chang L Junck D Schiff F Lieberman HA Fine M Mehta HI Robins LM De Angelis MD Groves VK Puduvalli V Levin C Conrad EA Maher K Aldape M Hayes L Letvak MJ Egorin R Capdeville R Kaplan AJ Murgo C Stiles MD Prados 2006 Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08 Clin Cancer Res 12 4899 4907 16914578 10.1158/1078-0432.CCR-06-0773 1:CAS:528:DC%2BD28XotFKgt70%3D (Pubitemid 44338577)
39. DR Macdonald TL Cascino SC Schold Jr JG Cairncross 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1277 1280 2358840 1:STN:280:DyaK3c3ptlyitQ%3D%3D (Pubitemid 20195640)
40. Chamberlain MC, Johnston SK (2011) Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. J Neurooncol 104(3):765-771
41. PY Wen WK Yung KR Lamborn AD Norden TF Cloughesy LE Abrey HA Fine SM Chang HI Robins K Fink LM De Angelis M Mehta E Di Tomaso J Drappatz S Kesari KL Ligon K Aldape RK Jain CD Stiles MJ Egorin MD Prados 2009 Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08) Neuro Oncol 11 853 860 10.1215/15228517-2009-010 19293394 10.1215/15228517-2009-010 1:CAS:528:DC%2BC3cXotVOruw%3D%3D